Carlos de Castro

Overview:

Clinical research projects have focused on new and innovative treatments for myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, adult leukemias, and lymphomas

Positions:

Professor of Medicine

Medicine, Hematologic Malignancies and Cellular Therapy
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1985

University of Texas at Dallas

Resident, Medicine

University of Texas at Dallas

Fellow in Hematology-Oncology, Medicine

Duke University

Grants:

EQAPOL - Years 2017 to 2024 - BASE

Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Director
Start Date
End Date

Eqapol Opt 1 -2018-2019

Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Medical Director
Start Date
End Date

EQAPOL Option 5

Administered By
Duke Human Vaccine Institute
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study To Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Administered By
Duke Cancer Institute
Awarded By
Apellis Pharmaceuticals, Inc
Role
Principal Investigator
Start Date
End Date

A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)

Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

Authors
Griffin, M; Hillmen, P; Szer, J; Weitz, IC; Roeth, A; Hoechsmann, B; Panse, J; Usuki, K; Kiladjian, J-J; De Castro, CM; Nishimori, H; Tan, L; Hamdani, M; Deschatelets, P; Francois, C; Grossi, F; Risitano, A; De Latour, RP
URI
https://scholars.duke.edu/individual/pub1483488
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
63
End Page
65

P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes

Authors
Frytak, JR; Henk, HJ; de Castro, CM; Halpern, R; Nelson, M
MLA Citation
Frytak, J. R., et al. “P132 Cost of transfusion dependency among managed care patients with myelodysplastic syndromes.” Leukemia Research, vol. 31, Elsevier BV, May 2007, pp. S111–12. Crossref, doi:10.1016/s0145-2126(07)70202-3.
URI
https://scholars.duke.edu/individual/pub927196
Source
crossref
Published In
Leukemia Research
Volume
31
Published Date
Start Page
S111
End Page
S112
DOI
10.1016/s0145-2126(07)70202-3

"Superiority of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Regardless of Prior Transfusion Requirement: Analysis at 16-weeks of PEGASUS Phase 3 Randomized Trial"

Authors
De latour, RP; De Castro, CM; Szer, J; Usuki, K; Hillmen, P; Griffin, M; Hamdani, M; Ajayi, T; Nishimori, H; Weitz, IC
URI
https://scholars.duke.edu/individual/pub1483489
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
189
End Page
190

Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Authors
Roeth, A; Hoechsmann, B; Griffin, M; De Castro, CM; Szer, J; Usuki, K; Soret, J; Hamdani, M; Ajayi, T; Sarda, SP; Panse, J
URI
https://scholars.duke.edu/individual/pub1483490
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
198
End Page
199

Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS)

Authors
Risitano, A; Weitz, IC; De Castro, CM; Kiladjian, J-J; Griffin, M; Nishimori, H; Hamdani, M; Ajayi, T; Baver, SB; de Latour, RP
URI
https://scholars.duke.edu/individual/pub1483491
Source
wos-lite
Published In
British Journal of Haematology
Volume
193
Published Date
Start Page
24
End Page
25